Details for New Drug Application (NDA): 022301

✉ Email this page to a colleague

NDA 022301 describes APRISO, which is a drug marketed by Salix and is included in one NDA. It is available from six suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the APRISO profile page.

The generic ingredient in APRISO is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Summary for 022301

Tradename:	APRISO
Applicant:	Salix
Ingredient:	mesalamine
Patents:	1

Pharmacology for NDA: 022301

Medical Subject Heading (MeSH) Categories for 022301

Anti-Inflammatory Agents, Non-Steroidal

Suppliers and Packaging for NDA: 022301

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301	NDA AUTHORIZED GENERIC	Teva Pharmaceuticals USA, Inc.	0093-9224	0093-9224-89	120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0093-9224-89)
APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301	NDA	Aphena Pharma Solutions - Tennessee, LLC	43353-884	43353-884-79	2160 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (43353-884-79)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE, EXTENDED RELEASE;ORAL			Strength	375MG
Approval Date:	Oct 31, 2008	TE:	AB	RLD:	Yes
Patent:	⤷ Sign Up	Patent Expiration:	May 1, 2030	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

Expired US Patents for NDA 022301

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	⤷ Sign Up	⤷ Sign Up
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	⤷ Sign Up	⤷ Sign Up
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	⤷ Sign Up	⤷ Sign Up
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	⤷ Sign Up	⤷ Sign Up
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	⤷ Sign Up	⤷ Sign Up
Salix	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.